Merck vs Merck in late-line kidney cancer
The group wants to improve on its own Welireg in a new phase 3 trial.
Allogene looks to consolidate its position
After a delay, the Alpha-3 study faces an April futility analysis.
Arvinas seeks to outdo Astellas
Early data are coming with the KRAS G12D degrader ARV-806.
Incyte’s JAK insurance policy heads for the clinic
A first-in-human trial of PRT12396 starts next month.
